A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
McDonagh
M S
MS
NHS Centre for Reviews and Dissemination, The University of York, UK.
Bachmann
L M
LM
Golder
S
S
Kleijnen
J
J
ter Riet
G
G
D000085:Acetates / Q000627:therapeutic use; D000789:Angina, Unstable / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D010091:Oximes / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000085:Acetates; D001713:Biphenyl Compounds; D010091:Oximes; D010455:Peptides; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D011759:Pyrrolidines; C107918:lefradafiban; D014443:Tyrosine; C084062:lamifiban; D000077466:Tirofiban; D000077542:Eptifibatide; C100917:sibrafiban